<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908557</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC 08 15</org_study_id>
    <nct_id>NCT00908557</nct_id>
  </id_info>
  <brief_title>Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT</brief_title>
  <acronym>LISYCOM</acronym>
  <official_title>Multicenter RCT to Assess the Impact of Improvements in Lexico-syntactic Readability and Good Practice in Writing on the Comprehension of Written Information Given to Patients Participating in Clinical Trials.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research Center of Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Strasbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Bichat, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Saint-Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center - biotherapy center of Saint-Louis, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center of Reunion island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center - Biotherapy center of Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center - Vacine center of Cochin - Pasteur, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacology unit of Créteil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Center, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principle objective of this randomised controlled trial is to assess whether an
      improvement in lexico-syntactic readability combined with adherence to French recommendations
      for good practice in writing the Information and Consent Form (ICF) given to patients
      participating in clinical trials, increases their understanding of the information compared
      to conventional written information, in real (not simulated) conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The quality of written information given to people participating in clinical trials is
      essential as by law all volunteers have to be informed of a certain number of key elements.
      Those elements that are necessary to understanding and making a decision as to whether to
      participate in the trial are presented to the volunteer in the information and consent
      document (ICD).

      Many terms used in the ICD are of necessity medical terms and sometimes difficult to
      understand for the person who may participate in the study.

      Several factors are involved when a reader receives a text, and one of the difficulties of
      intelligibility can be the lexico-syntactic readability.

      The lexico-syntactic readability is the only element of intelligibility that can be readily
      quantified, using the Flesch-Kincaid index. It is also an element that can be very easily
      modified without changing the sense of the information.

      In the QuIP-3 study, which we performed in 2003, it appeared that the lexico-syntactic
      readability of ICF is very low, lower than that of texts used in university level classics
      examinations. Furthermore, there is no correlation between the density of information and
      readability (QuIP-5 study).

      It seems to be necessary to assess the understanding of those participating in clinical
      trials in terms of logical and cognitive intelligibility (representativeness and
      interpretability of the information and consent forms). Indeed, a text may be unreadable
      according to the Flesch score, in lexico-syntactic terms, but perfectly understood and
      interpreted.

      As no questionnaire had been validated in French, we validated the &quot; Questionnaire
      d'Evaluation de la Compréhension de l'Information Ecrite par les Malades or QECIEM &quot;
      (Questionnaire measuring patient comprehension of written information) (QuIP-4). This
      questionnaire can be used to measure both objective and subjective general understanding by a
      patient to be included in a therapeutic study, irrespective of the pathology.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-score in part A (objective comprehension) of the QECIEM questionnaire of comprehension.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score in the QECIEM questionnaire of comprehension.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-scores in part B (subjective comprehension) of questionnaire of comprehension.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adhesion to proposed clinical trial protocols</measure>
    <time_frame>end of the study or end of Lisycom</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of complementary oral information on the QECIEM scores</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of readability by the investigator</measure>
    <time_frame>begin of the study or begin of Lisycom</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of refusals to sign informed consent form for the proposed trial.</measure>
    <time_frame>end of the study or end of Lisycom</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the QECIEMc</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Comprehension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving an information and consent form that has been modified using the LISYCOM methods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving a standard information and consent form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>readability improvement and good practice redaction</intervention_name>
    <description>improvement using Flesch readability index and good practice in redaction of informed consent documents.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>information based on the classic informed consent document</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject considered suitable to participate in one of the clinical trials selected for
             the LISYCOM study

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Illiteracy or inability to read French

          -  Neurological deficiency making reading impossible (attention disorders, aphasy, etc)

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc CRACOWSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Grenoble France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Paris A, Cracowski JL, Ravanel N, Cornu C, Gueyffier F, Deygas B, Guillot K, Bosson JL, Hommel M. [Readability of informed consent forms for subjects participating in biomedical research: updating is required]. Presse Med. 2005 Jan 15;34(1):13-8. French.</citation>
    <PMID>15685092</PMID>
  </reference>
  <reference>
    <citation>Paris A, Cracowski JL, Maison P, Radauceanu A, Cornu C, Hommel M. Impact of French 'Comités de Protection des Personnes' on the readability of informed consent documents (ICD) in biomedical research: more information, but not better information. Fundam Clin Pharmacol. 2005 Jun;19(3):395-9.</citation>
    <PMID>15910664</PMID>
  </reference>
  <reference>
    <citation>Okaïs C, Paris A, Cracowski JL. [Readability and information density in biomedical research]. Therapie. 2007 Jan-Feb;62(1):17-21. Epub 2007 Mar 21. French.</citation>
    <PMID>17374343</PMID>
  </reference>
  <reference>
    <citation>Paris A, Cornu C, Auquier P, Maison P, Radauceanu A, Brandt C, Salvat-Melis M, Hommel M, Cracowski JL. French adaptation and preliminary validation of a questionnaire to evaluate understanding of informed consent documents in phase I biomedical research. Fundam Clin Pharmacol. 2006 Feb;20(1):97-104.</citation>
    <PMID>16448400</PMID>
  </reference>
  <reference>
    <citation>Paris A, Nogueira da Gama Chaves D, Cornu C, Maison P, Salvat-Mélis M, Ribuot C, Brandt C, Bosson JL, Hommel M, Cracowski JL. Improvement of the comprehension of written information given to healthy volunteers in biomedical research: a single-blind randomized controlled study. Fundam Clin Pharmacol. 2007 Apr;21(2):207-14.</citation>
    <PMID>17391294</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Grenoble</investigator_affiliation>
    <investigator_full_name>AdministrateurCIC</investigator_full_name>
    <investigator_title>Pr Jean-Luc CRACOWSKI</investigator_title>
  </responsible_party>
  <keyword>Lexicosyntactic readability improvement</keyword>
  <keyword>phase II/III trials</keyword>
  <keyword>ethic</keyword>
  <keyword>Informed consent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

